Thanks@GMT2 Having spoken with Saul what seems like years ago...

I understand what you are saying but either way in spite of selection criteria Imugene are still working with relatively low sample sizes, a factor which I believe needs to be addressed in whatever way possible...Imugene has exceptional immunotherapies afoot that need to be fully explored at whatever the cost and difficulty, IMO.

Selection criteria is a complicated and at times restrictive measure based on existing medication, and yes Imugene has succeeded where others would not, being in a position to treat multiple cancer indications with Vaxinia, and combine Keytruda with it to boot. But could we have taken the medicine further and faster with Big Pharma support or a Nasdaq listing? What would the trade off have been? And would it have been worth it?

Harry I'm aware of the 3 patient issue, and would note my post is incorrect in making this statement. I guess the post was written with haste out of frustration at the inability of Vaxinia to reach more and more patients given its successful application pre clinically..thx for picking me up on that..

Thanks@GMT2 Having spoken with Saul what seems like years ago now and watching as Oncarlytics achieved strong pre clinical results with Amgen, I suppose I'm just so interested in moving ahead with the OASIS Trial at the fastest rate possible, as I'd sure most of us are....

WMHB